GlassScriptPhysician profile
Amanda L Christopher Thomas
NPI 1558734137
$14,464.48
in general payments reported to CMS, 2019-2025
54 companies · $3,476 in 2025
The $3,476 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,603 · 2022: $2,390 · 2023: $3,575 · 2024: $3,420 · 2025: $3,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $30.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,440.78 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $30.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,805.97 | 2021-2025 | |
| Novo Nordisk INC | $1,300.04 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $983.67 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $978.18 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $868.57 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Astrazeneca Pharmaceuticals LP | $827.94 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $582.76 | 2023-2025 | Jardiance, Synjardy, Spiriva Respimat |
| Bayer Healthcare Pharmaceuticals INC. | $495.71 | 2022-2025 | |
| Pfizer INC. | $443.33 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $401.80 | 2021-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $356.86 | 2023-2025 | Gemtesa |
| Amgen INC. | $348.88 | 2021-2025 | Otezla, Repatha, Otezla |
| Antares Pharma, INC. | $309.26 | 2024-2025 | Xyosted |
| Idorsia Pharmaceuticals US INC | $283.12 | 2022-2025 | Quviviq, Quviviq |
| Kowa Pharmaceuticals America, INC. | $231.95 | 2021-2025 | Livalo, Zoryve |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $223.50 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $200.10 | 2021-2023 | Trintellix |
| Astellas Pharma US INC | $175.68 | 2023-2024 | Veozah, Myrbetriq |
| Esperion Therapeutics, INC. | $168.83 | 2022-2025 | Nexletol |
| Axsome Therapeutics, INC. | $162.88 | 2025 | Symbravo, Auvelity |
| Supernus Pharmaceuticals, INC. | $148.81 | 2022 | Xyosted |
| Halozyme INC | $125.58 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $124.68 | 2021 | |
| Almatica Pharma LLC | $124.54 | 2024-2025 | Loreev Xr |
| Argenx US, INC. | $124.15 | 2023 | Vyvgart |
| Vivus LLC | $117.49 | 2021-2025 | Qsymia, Pancreaze |
| Teva Pharmaceuticals USA, INC. | $112.90 | 2021 | |
| Paratek Pharmaceuticals, INC. | $111.05 | 2022-2025 | Nuzyra |
| Daiichi Sankyo INC. | $108.24 | 2022-2023 | Injectafer |
| Amarin Pharma, INC. | $105.86 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.78 | 2023-2025 | Caplyta |
| Verity Pharmaceuticals INC. | $86.32 | 2024-2025 | Tlando |
| Neos Therapeutics, LP | $83.99 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $78.36 | 2021-2024 | Verquvo, Capvaxive, Gardasil |
| Tolmar, INC. | $77.85 | 2023-2025 | Jatenzo |
| Biohaven Pharmaceutical Holding Company LTD. | $65.37 | 2022 | |
| Medicure Pharma INC. | $61.74 | 2024-2025 | Zypitamag |
| Cequr Corporation | $61.21 | 2025 | Cequr Simplicity |
| Ironwood Pharmaceuticals, INC | $57.35 | 2024 | |
| Novartis Pharmaceuticals Corporation | $53.40 | 2023-2025 | |
| Hikma Pharmaceuticals USA | $51.43 | 2021-2024 | Ryaltris, Mitigare, Kloxxado |
| E.R. Squibb & Sons, L.L.C. | $50.33 | 2023-2024 | Eliquis |
| Phathom Pharmaceuticals, INC. | $43.07 | 2023-2025 | Voquezna |
| Optinose US, INC. | $37.56 | 2021 | |
| Medtronic, INC. | $33.63 | 2024 | Intellis Adaptivestim |
| Xeris Pharmaceuticals, INC. | $30.62 | 2023-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $30.37 | 2024-2025 | Korlym |
| Abbott Laboratories | $26.46 | 2024 | Freestyle Libre 3 |
| Lundbeck LLC | $19.05 | 2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $15.91 | 2023 | Xarelto |
| Shield Therapeutics INC | $14.88 | 2024 | |
| Horizon Therapeutics Plc | $14.76 | 2022 | |
| Phadia US INC. | $14.61 | 2025 | Immunocap |
| Organon LLC | $12.10 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.